Vaccines and uses thereof to induce an immune response to SARS-CoV2
AssigneeGeoVax, Inc.
InventorsMary Jo Hauser, Arban Domi, Farshad Guirakhoo
Life of this patent
Estimating the term…
Abstract
Provided herein are recombinant modified vaccinia Ankara (rMVA) viral vectors comprising heterologous nucleic acid inserts encoding one or more SARS-CoV2 proteins, peptides, or fragments thereof, operably linked to a promoter compatible with poxvirus expression systems that, upon expression, are capable of inducing protective immunity. The compositions can be used in a priming vaccination strategy or in a prime/boost vaccination strategy to provide immunity to SARS-CoV2 and variants thereof.
Claims28
A recombinant modified vaccinia Ankara (rMVA) viral vector comprising a heterologous nucleic acid sequence encoding a Spike(S) protein, a Membrane (M) protein, and an Envelope (E) protein derived from severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2) operably linked to one or more promoters compatible with poxvirus expression systems.
A recombinant modified vaccinia Ankara (rMVA) viral vector comprising a heterologous nucleic acid sequence encoding a stabilized Spike(S) protein comprising proline substitutions corresponding to amino acid positions K986 and V987 of SEQ ID NO:
- 8, a Membrane (M) protein, and an Envelope (E) protein derived from severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2) operably linked to a promoter compatible with poxvirus expression systems.
Dependencies are inferred from the claim text.